Low-dose granulocyte colony-stimulating factor overcomes neutropenia in the treatment of non-Hodgkin's lymphoma with higher cost-effectiveness

Takeshi Hara, Hisashi Tsurumi, Senji Kasahara, Nobuhiro Kanemura, Takeshi Yoshikawa, Naoe Goto, Yasushi Kojima, Toshiki Yamada, Michio Sawada, Takeshi Takahashi, Masami Oyama, Eiichi Tomita, Hisataka Moriwaki

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)

Abstract

To facilitate more economical medical care, we carried out a prospective study of whether a THP-COP regimen (cyclophosphamide, pirarubicin, vincristine, and prednisolone) with low-dose granulocyte colony-stimulating factor (G-CSF) would effectively treat non-Hodgkin's lymphoma (NHL). From April 2003 through March 2004, we enrolled 19 consecutive patients with newly diagnosed NHL treated at our hospital. The patients were divided into young and elderly groups. Each patient underwent chemotherapy with 8 courses of a THP-COP regimen with a 50-μg dose of lenograstim. Age- and sex-matched historical control patients (n = 141) received NHL diagnoses between 1998 and 2003. Each patient in the control group underwent the same chemotherapy and received a 100-μg dose of lenograstim. The mean (±SD) total amounts of G-CSF per cycle of chemotherapy were 332 ± 103 μg (young patients) and 345 ± 128 μg (elderly patients) in the low-dose group and 594 ± 439 μg (young) and 730 ± 551 μg (elderly) in the control group. The duration of fever in 1 cycle of chemotherapy was 0.3 ± 1.0 days (young) and 0.1 ± 0.8 days (elderly) in the low-dose group and 0.5 ± 1.3 days (young) and 0.8 ± 2.0 days (elderly) in the control group. A THP-COP regimen with low-dose G-CSF could be administered to NHL patients with safety. Administration of a 50-μg dose of lenograstim is sufficient and recommended for the treatment of NHL.

Original languageEnglish
Pages (from-to)430-436
Number of pages7
JournalInternational Journal of Hematology
Volume82
Issue number5
DOIs
Publication statusPublished - 2005
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Hematology

Fingerprint

Dive into the research topics of 'Low-dose granulocyte colony-stimulating factor overcomes neutropenia in the treatment of non-Hodgkin's lymphoma with higher cost-effectiveness'. Together they form a unique fingerprint.

Cite this